Halozyme Therapeutics, listed on Nasdaq, received a buy rating from TD Cowen, which was disclosed to the SEC.

The entities involved

• Halozyme Therapeutics →

  Nothing else this week.

• SEC →

  Slovak company

  • Director Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Sat 01:15
  • Director Lisa Jamieson sold shares of Forestar Group stock and disclosed the transaction to the SEC.Sat 00:53
• Nasdaq →

  American fully electronic stock exchange

  • An AI stock sell-off impacted Nasdaq on November 5, 2026, following the election results.Sat 01:20
  • BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.Sat 00:59

Related events

• Ligand Pharmaceuticals filed a transaction with the SEC, while Royal Bank of Canada lifted its target price, and the stock is listed on Nasdaq.Wed 13:17
• Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.Wed 00:24
• Corvus Pharmaceuticals began trading on the Nasdaq exchange on August 1, 2026.Aug 8
• Halozyme Therapeutics and Allarity Therapeutics are noted as healthcare companies competing for investment.Oct 24
• Monolithic Power Systems filed disclosures with the SEC, listed on Nasdaq, and saw Royal Bank of Canada increase its stock stake.Wed 12:41